FILE:HSP/HSP-8K-20040419062243.txt.gz
EVENTS:	Financial statements and exhibits	Regulation FD Disclosure
TEXT:
ITEM: Financial statements and exhibits
ITEM: Regulation FD Disclosure
Item 7.  Financial Statements and Exhibits
 
Item 9.  Regulation FD Disclosure
The registrant intends to present the materials attached to this report as Exhibit 99.1 in meetings with certain potential investors.
Limitation of Incorporation by Reference
                In accordance with the general instruction B.2 of Form 8-K, the information in this report is furnished pursuant to Item 9 and shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liability of that section.
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
 

Exhibit 99.1
Hos
pira, Inc.
 
April 2004
 
 
Saf
e Harbor
 
This material may contain forward-looking statements regarding Hospira, Inc., a Delaware company, within the meaning of the federal securities laws.  We intend these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements in the federal securities laws.  In some cases, you can identify these statements by our use of forward-looking words such as "may," "will," "should," "anticipate," "estimate," "expect," "plan," "believe," "predict," "potential," "project," "intend," "could" or similar expressions.  In particular, statements regarding our plans, strategies, prospects and expectations regarding our business as an independent public company are forward-looking statements.  You should be aware that these statements and any other forward-looking statements in this document only reflect our expectations and are not guarantees of performance.  These statements involve risks, uncertainties and assumptions.  Many of these risks, uncertainties and assumptions are beyond our control, and may cause actual results and performance to differ materially from our expectations.  Important factors that could cause our actual results to be materially different from our expectations include the risks and uncertainties set forth in the information statement under the heading "Risk Factors" in the most recent version of the Form 10 filed with the Securities and Exchange Commission, which are incorporated herein by reference.  Accordingly, you should not place undue reliance on the forward-looking statements contained in this material.  These forward-looking statements speak only as of the date on which the statements were made.  We undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.
Hos
pira Overview
Building on a Distinguished History
 
One of the largest global specialty pharmaceutical and medication delivery companies serving the hospital
 - 
                 
 
70 years of service to the hospital industry providing innovative, safe and cost-effective products
 - 
                 
 
#1 or #2 positions in each of its major product markets
 - 
                 
 
Long-term contracts with the major GPOs and IDNs
 - 
                 
[GRAPHIC]
Tra
nsaction Overview
 
Ben
efits of the Spin-Off
 
Spin-off provides enhanced strategic, operational and financial flexibility
 
Singular focus on our core hospital products business
 - 
                
 
Opportunity to build a lower cost, more efficient infrastructure
 - 
                
 
Employee incentives more aligned with shareholders
 - 
                
 
Do not have to compete for capital
 - 
                
 
Accelerating sales and profitability growth
 - 
                
Com
pelling Investment Opportunity
 
Spin-off enables Hospira to enhance growth and long-term profitability
 
Favorable demographics and market trends
 - 
                
 
Broad, strong presence in the hospital
 - 
                
 
Focused on customer needs through innovation and integration
 - 
                
 
Solid cash flows
 - 
                
 
Increased new product pipeline funding
 - 
                
Generic injectable pharmaceuticals
 - 
                     
Innovative medication delivery systems
 - 
                     
 
Substantial international expansion opportunity over time
 - 
                
 
Committed to improving margins and cash flows
 - 
                
Str
ong Vision, Values and Commitment
Focused and Energized: A New Company  A New Culture
 
 
Dee
p Management Experience
 
Uni
que Integrated Approach to Delivering Essential Hospital Drug Therapy
 
 
 
90% of ducts #1 or #2 in the U.S.
Pro
$2.6 Billion in 2003 Sales
 
Lar
ge Market Aided by Favorable Demographics
 
$9 billion U.S. market for our products
 - 
                 
 
Over the next 20 years, the number of people over 60 years old will increase by over 35 million
 - 
                 
 
Elderly tend to have the high acuity diseases that drive 70% of healthcare costs
 - 
                 
 
Hospitals continue to seek cost efficiencies
 - 
                 
 
[CHART]
 
Source: U.S. Census Bureau, 2004
Res
ponding to Market Needs
 
 
Pio
neer in Innovation and Safety
 
First to complete one of the most comprehensive bar coding programs for medication management
 - 
                 
 
Leader in needleless technology
 - 
                 
 
Proprietary delivery systems that reduce labor costs and promote safety
 - 
                 
 
PCA 3  first fully integrated drug delivery system
 - 
                 
 
MedNet to improve patient safety and hospital efficiency and compliance
 - 
                 
TM
 
Partnership with Cerner Corp. to develop point-of-care information systems for medication management
 - 
                 
 
[CHART]
Bus
iness Strategy
 
Bus
iness Segments
Spe
cialty Injectable Pharmaceuticals
Market
 
$4.4 billion U.S. market
 - 
                 
 
Projected market growth of 56%
 - 
                 
 
Continued need to reduce pharmaceutical expenditures
 - 
                 
 
Over $3 billion of proprietary drugs will face patent expiration by 2010
 - 
                 
 
[GRAPHIC]
 
pira's Strengths
Hos
 
 
Hospira Generic Pipeline  Expected # of Product Introductions
 
[CHART]
 
Med
ication Delivery Systems
Market
 
[GRAPHIC]
 
pira's Strengths
Hos
 
 
[GRAPHIC]
 
 
Con
tract Manufacturing
Market
 
Projected New Branded Injectable Product Approvals
 
[CHART]
 
Source: PharmSource
pira's Strengths
Hos
 
[GRAPHIC]
 
 
Int
ernational
Market
 
 
[GRAPHIC]
 
nificant Growth Potential
Sig
 
Rel
ationship with Abbott
Ensuring a Successful Transition Period
 
 
Fin
ancial Overview
 
Fin
ancial Performance
($MM)
 
Obl
igation to Abbott
 
Obligation to Abbott = $1 billion
 
$700 million dividend to Abbott on day one, funded by debt
 -     
 
$300 million of future payments to purchase International assets
 -     
Completed over 24 months
 -      
Funded by internally generated cash
 -      
 
$300 million 5-year revolving credit facility will be available to provide additional liquidity
Mov
ing from a Division of Abbott to a Fully Independent Company
Ongoing incremental expenses to run an independent company
 -     
 
 
Projected transitional, one-time expenses
 -     
 
 
Note:  (1) Annualized projected expenses
Cas
h Flow
($MM)
 
Cash flow available to fund ongoing operations and investments
 
 
Cash Flow from Operations improving in 2005 and beyond
 -     
Expect to be cash positive in 2006 after completing purchase of International assets
 -     
2004 jections
Pro
 
Sales of approximately $2.5 billion
 -     
 
Earnings:
 -     
 
 
Note: (1) Mid-point of projected range. One-time transition costs estimated to be $0.15 to $0.19 per share in 2004.
Fin
ancial Outlook
 
 
Com
pelling Investment Opportunity
 
Spin-off enables Hospira to enhance growth and long-term profitability
 
Favorable demographics and market trends
 -     
 
Broad, strong presence in the hospital
 -     
 
Focused on customer needs through innovation and integration
 -     
 
Solid cash flows
 -     
 
Increased new product pipeline funding
 -     
Generic injectable pharmaceuticals
 -     
Innovative medication delivery systems
 -     
 
Substantial international expansion opportunity over time
 -     
Committed to improving margins and cash flows
 -     


